Clinical and Immune Impact of Mycobacterium bovis BCG Vaccination Scarring
Open Access
- 1 November 2002
- journal article
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 70 (11), 6284-6293
- https://doi.org/10.1128/iai.70.11.6188-6195.2002
Abstract
The World Health Organization recommends Mycobacterium bovis BCG vaccination in areas of high tuberculosis prevalence. BCG's clinical and immune effects, not necessarily Mycobacterium tuberculosis specific, are unclear. BCG vaccine scarring often is used as a surrogate marker of vaccination or of effective vaccination. We evaluated BCG scarring status in relation to clinical findings and outcome in 700 hospitalized Malawians, of whom 32 had M. tuberculosis bloodstream infections (BSI) (10 of whom had cellular immune studies done) and of whom 48 were infants M. tuberculosis BSI. In M. tuberculosis BSI patients, scarring was unrelated to mortality, vital signs, or clinical symptoms but those with scarring had higher proportions of memory and activated T cells and more type 2-skewed cytokine profiles. Infants with either BCG scarring ( n = 10) or BCG lesional inflammation ( n = 5) had no symptoms of sepsis, but 18 of 33 infants without BCG vaccination lesions did. Those with BCG lesions had localized infections more often than did those without BCG lesions. These infants also had lower median percentages of lymphocytes spontaneously making interleukin-4 (IL-4) or tumor necrosis factor alpha (TNF-α) and lower ratios of T cells spontaneously making IL-4 to T cells making IL-6. Thus, we found that, in older patients, BCG vaccine scarring was not associated with M. tuberculosis -specific or nonspecific clinical protection. Those with M. tuberculosis BSI and scarring had immune findings suggesting previous M. tuberculosis antigen exposure and induction of a type 2 cytokine pattern with acute reexposure. It is unlikely that this type 2 pattern would be protective against mycobacteria, which require a type 1 response for effective containment. In infants M. tuberculosis -specific, anti-inflammatory cytokine profile. That the vaccinated infants had a greater frequency of localized infections and lesser frequency of sepsis symptoms suggests that this postvaccination cytokine pattern may provide some non- M. tuberculosis -specific clinical benefits.Keywords
This publication has 40 references indexed in Scilit:
- Impact of tuberculosis (TB) on HIV-1 activity in dually infected patientsClinical and Experimental Immunology, 2001
- Natural T, γδ, and NK Cells in Mycobacterial,Salmonella,and Human Immunodeficiency Virus InfectionsThe Journal of Infectious Diseases, 2000
- Immunological Cytokine Correlates of Protective Immunity and Pathogenesis in LeprosyScandinavian Journal of Immunology, 2000
- Use of two methods of analysis to estimate the annual rate of tuberculosis infection in Southern AlgeriaTubercle and Lung Disease, 1996
- Changes in urinary cytokines and soluble intercellular adhesion molecule-1 (ICAM-1) in bladder cancer patients after Bacillus Calmette—Guérin (BCG) immunotherapyClinical and Experimental Immunology, 1995
- Protective Effect of BCG against Tuberculous Meningitis and Miliary Tuberculosis: A Meta-AnalysisInternational Journal of Epidemiology, 1993
- Tuberculin response in preterm infants after BCG vaccination at birth.Archives of Disease in Childhood, 1993
- Sensitivity to PPD tuberculin and M. scrofulaceum sensitin in schoolchildren BCG vaccinated at birthTubercle and Lung Disease, 1992
- Evaluation of BCG at birth in the United Arab EmiratesTubercle, 1990
- The present and future role of BCG vaccine in tuberculosis controlBiologicals, 1990